Patents by Inventor Yu-Ching Eugene Pan

Yu-Ching Eugene Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
    Patent number: 8110187
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: February 7, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
    Patent number: 6683046
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth. Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: January 27, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
    Publication number: 20030204059
    Abstract: The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.
    Type: Application
    Filed: October 8, 2002
    Publication date: October 30, 2003
    Applicant: Hoffmann-LaRoche
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan
  • Monoclonal antibodies to cytotoxic lymphocyte maturation factor
    Patent number: 5780597
    Abstract: The present invention relates to antibodies which bind to a novel cytotoxic lymphocyte maturation factor. When bound to the cytotoxic lymphocyte maturation factor, the antibodies can neutralize bioactivity of the factor.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 14, 1998
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maurice Kent Gately, Ulrich Andreas Gubler, Jeffrey David Hulmes, Frank John Podlaski, Alvin Seth Stern, Richard Anthony Chizzonite, Yu-Ching Eugene Pan